These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Preclinical formulations for discovery and toxicology: physicochemical challenges. Neervannan S Expert Opin Drug Metab Toxicol; 2006 Oct; 2(5):715-31. PubMed ID: 17014391 [TBL] [Abstract][Full Text] [Related]
24. Safety evaluation of biological drugs: what are toxicology studies in primates telling us? Baldrick P Regul Toxicol Pharmacol; 2011 Mar; 59(2):227-36. PubMed ID: 20937341 [TBL] [Abstract][Full Text] [Related]
25. The application of discovery toxicology and pathology towards the design of safer pharmaceutical lead candidates. Kramer JA; Sagartz JE; Morris DL Nat Rev Drug Discov; 2007 Aug; 6(8):636-49. PubMed ID: 17643090 [TBL] [Abstract][Full Text] [Related]
26. Prediction and classification of drug toxicity using probabilistic modeling of temporal metabolic data: the consortium on metabonomic toxicology screening approach. Ebbels TM; Keun HC; Beckonert OP; Bollard ME; Lindon JC; Holmes E; Nicholson JK J Proteome Res; 2007 Nov; 6(11):4407-22. PubMed ID: 17915905 [TBL] [Abstract][Full Text] [Related]
27. A critical evaluation of developmental and reproductive toxicology in nonhuman primates. Faqi AS Syst Biol Reprod Med; 2012 Feb; 58(1):23-32. PubMed ID: 22239078 [TBL] [Abstract][Full Text] [Related]
28. Developmental and reproductive toxicology studies in nonhuman primates. Chellman GJ; Bussiere JL; Makori N; Martin PL; Ooshima Y; Weinbauer GF Birth Defects Res B Dev Reprod Toxicol; 2009 Dec; 86(6):446-62. PubMed ID: 20025046 [TBL] [Abstract][Full Text] [Related]
29. Extrapolating from animal studies to the efficacy in humans of a pretreatment combination against organophosphate poisoning. Levy A; Cohen G; Gilat E; Kapon J; Dachir S; Abraham S; Herskovitz M; Teitelbaum Z; Raveh L Arch Toxicol; 2007 May; 81(5):353-9. PubMed ID: 17009047 [TBL] [Abstract][Full Text] [Related]
30. Assessment of the safety of drugs for animals. Robens JF Vet Hum Toxicol; 1979 Feb; 21(1):12-23. PubMed ID: 425289 [TBL] [Abstract][Full Text] [Related]
31. Regulatory forum opinion piece*: immunotoxicology assessments in nonhuman primates--challenges and opportunities. Lebrec HN Toxicol Pathol; 2013; 41(3):548-51. PubMed ID: 22886347 [TBL] [Abstract][Full Text] [Related]
32. Pharmacologic considerations in the design of toxicology experiments. Darby TD Clin Toxicol; 1978 Feb; 12(2):229-38. PubMed ID: 648118 [TBL] [Abstract][Full Text] [Related]
33. Considerations for the sensible use of rodent models of inflammatory disease in predicting efficacy of new biological therapeutics in the clinic. Arnett HA; Viney JL Adv Drug Deliv Rev; 2007 Sep; 59(11):1084-92. PubMed ID: 17804112 [TBL] [Abstract][Full Text] [Related]
34. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning. Petersen SL Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527 [TBL] [Abstract][Full Text] [Related]
35. Strategies and experimental models for evaluating anesthetics: effects on the developing nervous system. Wang C; Slikker W Anesth Analg; 2008 Jun; 106(6):1643-58. PubMed ID: 18499593 [TBL] [Abstract][Full Text] [Related]
36. Simian retroviruses: infection and disease--implications for immunotoxicology research in primates. Lerche NW J Immunotoxicol; 2010; 7(2):93-101. PubMed ID: 20433415 [TBL] [Abstract][Full Text] [Related]
37. Principles of pharmacodynamics and their applications in veterinary pharmacology. Lees P; Cunningham FM; Elliott J J Vet Pharmacol Ther; 2004 Dec; 27(6):397-414. PubMed ID: 15601436 [TBL] [Abstract][Full Text] [Related]
38. Evaluation of rodent-only toxicology for early clinical trials with novel cancer therapeutics. Newell DR; Burtles SS; Fox BW; Jodrell DI; Connors TA Br J Cancer; 1999 Nov; 81(5):760-8. PubMed ID: 10555743 [TBL] [Abstract][Full Text] [Related]
39. The role of the toxicologic pathologist in the biopharmaceutical industry. van Tongeren S; Fagerland JA; Conner MW; Diegel K; Donnelly K; Grubor B; Lopez-Martinez A; Bolliger AP; Sharma A; Tannehill-Gregg S; Turner PV; Wancket LM Int J Toxicol; 2011 Oct; 30(5):568-82. PubMed ID: 21878555 [TBL] [Abstract][Full Text] [Related]